Davion Healthcare's F-1 registration statement becomes effective

Davion Healthcare Plc (NASDAQ: DAVI) announced that its Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission on November 7, 2025, has become automatically effective under Section 8(a) of the Securities Act of 1933.

The medical technology company also filed a Form 8-A to register its ordinary shares under Section 12(b) of the Securities Exchange Act of 1934 in connection with the F-1's effectiveness.

Davion stated it is completing remaining administrative steps with The Nasdaq Stock Market regarding admission of its ordinary shares for trading. The company said it will make a further announcement once it receives confirmation of its listing date.

The Dublin, Ireland-based company develops non-invasive home tests for early-stage identification of medical anomalies including cancer. Its lead product, BreastCheck, is an FDA-registered at-home breast health screening test that uses a thermosensitive patch and companion mobile app. The company said BreastCheck is set for commercial launch by the end of the first half of 2026.

Davion operates under a capital-light, licensing-led model, designing and registering proprietary monitoring tools while partnering with third parties for manufacturing and distribution. The company's product pipeline includes FootFlow for foot temperature monitoring, Testic for testicular health monitoring, and ThermaDerm for skin anomaly detection.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Paramount Skydance clears global regulators for WBD deal, faces state AG suit
• Waymo wins California approval to expand ride-hailing service